CD8A and cancer: Our study clearly indicates that the combination of OMT and DDP synergistically enhanced NSCLC cells growth inhibition, CD8+/Treg ratio and CD8+ T cells anti-tumor immune response with the upregulation of miR-155 and the silence of SOCS1. It has been reported that cancer immunotherapy has been a hot spot in the treatment of NSCLC (34).